227 related articles for article (PubMed ID: 12093183)
1. Quasispecies heterogeneity and constraints on the evolution of the 5' noncoding region of hepatitis C virus (HCV): relationship with HCV resistance to interferon-alpha therapy.
Soler M; Pellerin M; Malnou CE; Dhumeaux D; Kean KM; Pawlotsky JM
Virology; 2002 Jun; 298(1):160-73. PubMed ID: 12093183
[TBL] [Abstract][Full Text] [Related]
2. Lack of clinical significance of variability in the internal ribosome entry site of hepatitis C virus.
Thelu MA; Drouet E; Hilleret MN; Zarski JP
J Med Virol; 2004 Mar; 72(3):396-405. PubMed ID: 14748063
[TBL] [Abstract][Full Text] [Related]
3. Virological effects of ISIS 14803, an antisense oligonucleotide inhibitor of hepatitis C virus (HCV) internal ribosome entry site (IRES), on HCV IRES in chronic hepatitis C patients and examination of the potential role of primary and secondary HCV resistance in the outcome of treatment.
Soler M; McHutchison JG; Kwoh TJ; Dorr FA; Pawlotsky JM
Antivir Ther; 2004 Dec; 9(6):953-68. PubMed ID: 15651754
[TBL] [Abstract][Full Text] [Related]
4. Selection of genetic variants of the 5' noncoding region of hepatitis C virus occurs only in patients responding to interferon alpha therapy.
Lu M; Wiese M; Roggendorf M
J Med Virol; 1999 Oct; 59(2):146-53. PubMed ID: 10459148
[TBL] [Abstract][Full Text] [Related]
5. IRES complexity before IFN-alpha treatment and evolution of the viral load at the early stage of treatment in peripheral blood mononuclear cells from chronic hepatitis C patients.
Thélu MA; Leroy V; Ramzan M; Dufeu-Duchesne T; Marche P; Zarski JP
J Med Virol; 2007 Mar; 79(3):242-53. PubMed ID: 17245718
[TBL] [Abstract][Full Text] [Related]
6. Deep sequencing and phylogenetic analysis of variants resistant to interferon-based protease inhibitor therapy in chronic hepatitis induced by genotype 1b hepatitis C virus.
Sato M; Maekawa S; Komatsu N; Tatsumi A; Miura M; Muraoka M; Suzuki Y; Amemiya F; Takano S; Fukasawa M; Nakayama Y; Yamaguchi T; Uetake T; Inoue T; Sato T; Sakamoto M; Yamashita A; Moriishi K; Enomoto N
J Virol; 2015 Jun; 89(11):6105-16. PubMed ID: 25810555
[TBL] [Abstract][Full Text] [Related]
7. Genetic heterogeneity of hypervariable region 1 of the hepatitis C virus (HCV) genome and sensitivity of HCV to alpha interferon therapy.
Sandres K; Dubois M; Pasquier C; Payen JL; Alric L; Duffaut M; Vinel JP; Pascal JP; Puel J; Izopet J
J Virol; 2000 Jan; 74(2):661-8. PubMed ID: 10623727
[TBL] [Abstract][Full Text] [Related]
8. Clinical evaluation of two methods for genotyping hepatitis C virus based on analysis of the 5' noncoding region.
Nolte FS; Green AM; Fiebelkorn KR; Caliendo AM; Sturchio C; Grunwald A; Healy M
J Clin Microbiol; 2003 Apr; 41(4):1558-64. PubMed ID: 12682145
[TBL] [Abstract][Full Text] [Related]
9. Genetic distance and heterogenecity between quasispecies is a critical predictor to IFN response in Egyptian patients with HCV genotype-4.
Zekri AR; El-Din HM; Bahnassy AA; Khaled MM; Omar A; Fouad I; El-Hefnewi M; Thakeb F; El-Awady M
Virol J; 2007 Feb; 4():16. PubMed ID: 17300723
[TBL] [Abstract][Full Text] [Related]
10. Genetic complexity of the hypervariable region 1 (HVR1) of hepatitis C virus (HCV): influence on the characteristics of the infection and responses to interferon alfa therapy in patients with chronic hepatitis C.
Pawlotsky JM; Pellerin M; Bouvier M; Roudot-Thoraval F; Germanidis G; Bastie A; Darthuy F; Rémiré J; Soussy CJ; Dhumeaux D
J Med Virol; 1998 Apr; 54(4):256-64. PubMed ID: 9557291
[TBL] [Abstract][Full Text] [Related]
11. Positional effect of mutations in 5'UTR of hepatitis C virus 4a on patients' response to therapy.
El Awady MK; Azzazy HM; Fahmy AM; Shawky SM; Badreldin NG; Yossef SS; Omran MH; Zekri AR; Goueli SA
World J Gastroenterol; 2009 Mar; 15(12):1480-6. PubMed ID: 19322922
[TBL] [Abstract][Full Text] [Related]
12. Genetic Variability of Hepatitis C Virus (HCV) 5' Untranslated Region in HIV/HCV Coinfected Patients Treated with Pegylated Interferon and Ribavirin.
Bukowska-Ośko I; Pawełczyk A; Perlejewski K; Kubisa N; Caraballo Cortés K; Rosińska M; Płoski R; Fic M; Kaźmierczak J; Popiel M; Ząbek P; Horban A; Radkowski M; Laskus T
PLoS One; 2015; 10(5):e0125604. PubMed ID: 25932941
[TBL] [Abstract][Full Text] [Related]
13. Analysis of HCV co-infection with occult hepatitis B virus in patients undergoing IFN therapy.
Khattab E; Chemin I; Vuillermoz I; Vieux C; Mrani S; Guillaud O; Trepo C; Zoulim F
J Clin Virol; 2005 Jun; 33(2):150-7. PubMed ID: 15911431
[TBL] [Abstract][Full Text] [Related]
14. Nucleotide sequence variations in the internal ribosome entry site of hepatitis C virus-1b: no association with efficacy of interferon therapy or serum HCV-RNA levels.
Yamamoto C; Enomoto N; Kurosaki M; Yu SH; Tazawa J; Izumi N; Marumo F; Sato C
Hepatology; 1997 Dec; 26(6):1616-20. PubMed ID: 9398006
[TBL] [Abstract][Full Text] [Related]
15. Evolution of hepatitis C virus quasispecies during ribavirin and interferon-alpha-2b combination therapy and interferon-alpha-2b monotherapy.
Arataki K; Kumada H; Toyota K; Ohishi W; Takahashi S; Tazuma S; Chayama K
Intervirology; 2006; 49(6):352-61. PubMed ID: 16926548
[TBL] [Abstract][Full Text] [Related]
16. Evolution of the hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving alpha interferon therapy.
Pawlotsky JM; Germanidis G; Frainais PO; Bouvier M; Soulier A; Pellerin M; Dhumeaux D
J Virol; 1999 Aug; 73(8):6490-9. PubMed ID: 10400744
[TBL] [Abstract][Full Text] [Related]
17. Correlation between translation efficiency and outcome of combination therapy in chronic hepatitis C genotype 3.
Yasmeen A; Hamid S; Granath FN; Lindström H; Elliott RM; Siddiqui AA; Persson MA
J Viral Hepat; 2006 Feb; 13(2):87-95. PubMed ID: 16436126
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C virus (HCV) 5'NC sequence variants and their association with hepatitis C risk groups.
Krekulova L; Rehak V; Riley LW
J Clin Virol; 2005 Apr; 32(4):300-4. PubMed ID: 15780809
[TBL] [Abstract][Full Text] [Related]
19. Cell type-specific enhancement of hepatitis C virus internal ribosome entry site-directed translation due to 5' nontranslated region substitutions selected during passage of virus in lymphoblastoid cells.
Lerat H; Shimizu YK; Lemon SM
J Virol; 2000 Aug; 74(15):7024-31. PubMed ID: 10888641
[TBL] [Abstract][Full Text] [Related]
20. Evolution of naturally occurring 5' non-translated region variants of hepatitis C virus genotype 1b in selectable replicons.
van Leeuwen HC; Reusken CBEM; Roeten M; Dalebout TJ; Riezu-Boj JI; Ruiz J; Spaan WJM
J Gen Virol; 2004 Jul; 85(Pt 7):1859-1866. PubMed ID: 15218170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
